Rapid anxiolytic effects of a 5-HT4 receptor agonist are mediated by a neurogenesis-independent mechanism

Neuropsychopharmacology

Volumn 39, Issue 6, 2014, Pages 1366-1378

  Mendez David, Indira ^a   David, Denis J ^a   Darcet, Flavie ^a   Wu, Melody V ^b,c   Kerdine Römer, Saadia ^a   Gardier, Alain M ^a   Hen, René ^b,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

anxiolytic; fast onset; neurogenesis

Indexed keywords

1 (4 AMINO 5 CHLORO 2 METHOXYPHENYL) 3 (1 BUTYL 4 PIPERIDINYL) 1 PROPANONE; 5 FLUORO 2 METHOXY 1H INDOLE 3 CARBOXYLIC ACID 1 [2 (METHYLSULFONAMIDO)ETHYL] 4 PIPERIDINYLMETHYL ESTER; FLUOXETINE; 1 METHYL 3 INDOLECARBOXYLIC ACID [1 [2 (METHYLSULFONYLAMINO)ETHYL] 4 PIPERIDINYLMETHYL] ESTER; ANILINE DERIVATIVE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CORTICOSTERONE; INDOLE DERIVATIVE; PIPERIDINE DERIVATIVE; SEROTONIN 4 AGONIST; SEROTONIN 4 ANTAGONIST; SEROTONIN 4 RECEPTOR; SULFONAMIDE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ANXIETY; ARTICLE; BRAIN NERVE CELL; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; DEPRESSION; DRUG MECHANISM; HIPPOCAMPUS; MALE; MOUSE; MOUSE MODEL; NERVOUS SYSTEM DEVELOPMENT; NEWBORN; NONHUMAN; PRIORITY JOURNAL; TRANQUILIZING ACTIVITY; X IRRADIATION; ANIMAL; C57BL MOUSE; COMORBIDITY; COMPARATIVE STUDY; DEPRESSIVE DISORDER; DISEASE MODEL; DRUG EFFECTS; DRUG THERAPY; EPIDEMIOLOGY; METABOLISM; NERVE CELL; PATHOPHYSIOLOGY; PHYSIOLOGY; TIME;

ANILINE COMPOUNDS; ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY; COMORBIDITY; CORTICOSTERONE; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; FLUOXETINE; HIPPOCAMPUS; INDOLES; MALE; MICE; MICE, INBRED C57BL; NEUROGENESIS; NEURONS; PIPERIDINES; RECEPTORS, SEROTONIN, 5-HT4; SEROTONIN 5-HT4 RECEPTOR AGONISTS; SEROTONIN 5-HT4 RECEPTOR ANTAGONISTS; SULFONAMIDES; TIME FACTORS;

EID: 84900827276     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.332     Document Type: Article

References (55)

1. Artigas F (2013). Developments in the field of antidepressants, where do we go now? Eur Neuropsychopharmacol (e-pub ahead of print; doi:10.1016/j. euroneuro.2013.04.013).
2. Ase AR, Reader TA, Hen R, Riad M, Descarries L (2001). Regional changes in density of serotonin transporter in the brain of 5- HT1A and 5-HT1B knockout mice, and of serotonin innervation in the 5-HT1B knockout. J Neurochem 78: 619-630. (Pubitemid 32729990)
3. Bockaert J, Claeysen S, Compan V, Dumuis A (2004). 5-HT4 receptors. Curr Drug Targets CNS Neurol Disord 3: 39-51.
4. Bockaert J, Claeysen S, Compan V, Dumuis A (2008). 5-HT(4) receptors: history, molecular pharmacology and brain functions. Neuropharmacology 55: 922-931.
5. Burghardt NS, Bauer EP (2013). Acute and chronic effects of selective serotonin reuptake inhibitor treatment on fear conditioning: Implications for underlying fear circuits. Neuroscience 247: 253-272.
6. Cachard-Chastel M, Lezoualc'h F, Dewachter I, Delomenie C, Croes S, Devijver H et al (2007). 5-HT4 receptor agonists increase sAPPalpha levels in the cortex and hippocampus of male C57BL/6j mice. Br J Pharmacol 150: 883-892. (Pubitemid 46536635)
7. Compan V, Zhou M, Grailhe R, Gazzara RA, Martin R, Gingrich J et al (2004). Attenuated response to stress and novelty and hypersensitivity to seizures in 5-HT4 receptor knock-out mice. J Neurosci 24: 412-419. (Pubitemid 38112372)
8. Conductier G, Dusticier N, Lucas G, Cote F, Debonnel G, Daszuta A et al (2006). Adaptive changes in serotonin neurons of the raphe nuclei in 5-HT(4) receptor knock-out mouse. Eur J Neurosci 24: 1053-1062. (Pubitemid 44268136)
9. Costall B, Naylor RJ (1997). The influence of 5-HT2 and 5-HT4 receptor antagonists to modify drug induced disinhibitory effects in the mouse light/dark test. Br J Pharmacol 122: 1105-1118. (Pubitemid 27494225)
10. Couillard-Despres S, Winner B, Schaubeck S, Aigner R, Vroemen M, Weidner N et al (2005). Doublecortin expression levels in adult brain reflect neurogenesis. Eur J Neurosci 21: 1-14. (Pubitemid 40193870)
11. David DJ, Samuels BA, Rainer Q, Wang JW, Marsteller D, Mendez I et al (2009). Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. Neuron 62: 479-493.
12. David DJ, Wang J, Samuels BA, Rainer Q, David I, Gardier AM et al (2010). Implications of the functional integration of adult-born hippocampal neurons in anxiety-depression disorders. Neuroscientist 16: 578-591.
13. Denny CA, Burghardt NS, Schachter DM, Hen R, Drew MR (2012). 4- to 6-week-old adult-born hippocampal neurons influence novelty-evoked exploration and contextual fear conditioning. Hippocampus 22: 1188-1201.
14. Egeland M, Warner-Schmidt J, Greengard P, Svenningsson P (2011). Co-expression of serotonin 5-HT(1B) and 5-HT(4) receptors in p11 containing cells in cerebral cortex, hippocampus, caudate-putamen and cerebellum. Neuropharmacology 61: 442-450.
15. Eglen RM, Bonhaus DW, Johnson LG, Leung E, Clark RD (1995). Pharmacological characterization of two novel and potent 5-HT4 receptor agonists, RS 67333 and RS 67506, in vitro and in vivo. Br J Pharmacol 115: 1387-1392.
16. Freret T, Bouet V, Quiedeville A, Nee G, Dallemagne P, Rochais C et al (2012). Synergistic effect of acetylcholinesterase inhibition (donepezil) and 5-HT(4) receptor activation (RS67333) on object recognition in mice. Behav Brain Res 230: 304-308.
17. Gale JD, Grossman CJ, Whitehead JW, Oxford AW, Bunce KT, Humphrey PP (1994). GR113808: a novel, selective antagonist with high affinity at the 5-HT4 receptor. Br J Pharmacol 111: 332-338. (Pubitemid 24148746)
18. Ge J, Barnes NM (1996). 5-HT4 receptor-mediated modulation of 5-HT release in the rat hippocampus in vivo. Br J Pharmacol 117: 1475-1480.
19. Gomez-Lazaro E, Garmendia L, Beitia G, Perez-Tejada J, Azpiroz A, Arregi A (2012). Effects of a putative antidepressant with a rapid onset of action in defeated mice with different coping strategies. Prog Neuropsychopharmacol Biol Psychiatry 38: 317-327.
20. Gould TD (2011). Mood and Anxiety Related Phenotypes in Mice Characterization Using Behavioral Tests Volume II. Neuromethods Ser. Humana Press Springer Distributor, Secaucus, New York, NY, USA.
21. Guilloux JP, David I, Pehrson A, Guiard BP, Reperant C, Orvoen S et al (2013). Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioral and neurogenesis outcomes in mice. Neuropharmacology 73: 147-159.
22. Jennings KA, Licht CL, Bruce A, Lesch KP, Knudsen GM, Sharp T (2012). Genetic variation in 5-hydroxytryptamine transporter expression causes adaptive changes in 5-HT(4) receptor levels. Int J Neuropsychopharmacol 15: 1099-1107.
23. Kato M, Serretti A (2010). Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 15: 473-500.
24. Kennett GA, Wood MD, Bright F, Trail B, Riley G, Holland V et al (1997). SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 36: 609-620. (Pubitemid 27272106)
25. Kheirbek MA, Klemenhagen KC, Sahay A, Hen R (2012). Neurogenesis and generalization: a new approach to stratify and treat anxiety disorders. Nat Neurosci 15: 1613-1620.
26. Klempin F, Babu H, De Pietri Tonelli D, Alarcon E, Fabel K, Kempermann G (2010). Oppositional effects of serotonin receptors 5-HT1a, 2, and 2c in the regulation of adult hippocampal neurogenesis. Front Mol Neurosci 3: pii: 14.
27. Kobayashi K, Haneda E, Higuchi M, Suhara T, Suzuki H (2012). Chronic fluoxetine selectively upregulates dopamine D(1)-like receptors in the hippocampus. Neuropsychopharmacology 37: 1500-1508.
28. Kobayashi K, Ikeda Y, Sakai A, Yamasaki N, Haneda E, Miyakawa T et al (2010). Reversal of hippocampal neuronal maturation by serotonergic antidepressants. Proc Natl Acad Sci USA 107: 8434-8439.
29. Lamirault L, Simon H (2001). Enhancement of place and object recognition memory in young adult and old rats by RS 67333, a partial agonist of 5-HT4 receptors. Neuropharmacology 41: 844-853. (Pubitemid 33001418)
30. Licht CL, Knudsen GM, Sharp T (2010). Effects of the 5-HT(4) receptor agonist RS67333 and paroxetine on hippocampal extracellular 5-HT levels. Neurosci Lett 476: 58-61.
31. Lucas G (2009). Serotonin receptors, type 4: a new hope? Curr Drug Targets 10: 1085-1095.
32. Lucas G, Compan V, Charnay Y, Neve RL, Nestler EJ, Bockaert J et al (2005). Frontocortical 5-HT4 receptors exert positive feedback on serotonergic activity: viral transfections, subacute and chronic treatments with 5-HT4 agonists. Biol Psychiatry 57: 918-925. (Pubitemid 40488361)
33. Lucas G, Debonnel G (2002). 5-HT4 receptors exert a frequencyrelated facilitatory control on dorsal raphe nucleus 5-HT neuronal activity. Eur J Neurosci 16: 817-822. (Pubitemid 35463573)
34. Lucas G, Du J, Romeas T, Mnie-Filali O, Haddjeri N, Pineyro G et al (2010). Selective serotonin reuptake inhibitors potentiate the rapid antidepressant-like effects of serotonin4 receptor agonists in the rat. PLoS One 5: e9253.
35. Lucas G, Rymar VV, Du J, Mnie-Filali O, Bisgaard C, Manta S et al (2007). Serotonin(4) (5-HT(4)) receptor agonists are putative antidepressants with a rapid onset of action. Neuron 55: 712-725. (Pubitemid 47334877)
36. Lucchelli A, Santagostino-Barbone MG, Barbieri A, Candura SM, Tonini M (1995). The interaction of antidepressant drugs with central and peripheral (enteric) 5-HT3 and 5-HT4 receptors. Br J Pharmacol 114: 1017-1025.
37. Mendez-David I, Hen R, Gardier AM, David DJ (2013). Adult hippocampal neurogenesis: an actor in the antidepressant-like action. Ann Pharm Fr 71: 143-149.
38. Meshi D, Drew MR, Saxe M, Ansorge MS, David D, Santarelli L et al (2006). Hippocampal neurogenesis is not required for behavioral effects of environmental enrichment. Nature Neuroscience 9: 729-731.
39. Nestler EJ, Gould E, Manji H, Buncan M, Duman RS, Greshenfeld HK et al (2002). Preclinical models: status of basic research in depression. Biol Psychiatry 52: 503-528. (Pubitemid 35284020)
40. Pascual-Brazo J, Castro E, Diaz A, Valdizan EM, Pilar-Cuellar F, Vidal R et al (2012). Modulation of neuroplasticity pathways and antidepressant-like behavioural responses following the shortterm (3 and 7 days) administration of the 5-HT(4) receptor agonist RS67333. Int J Neuropsychopharmacol 15: 631-643.
41. Quesseveur G, David DJ, Gaillard MC, Pla P, Wu MV, Nguyen HT et al (2013). BDNF overexpression in mouse hippocampal astrocytes promotes local neurogenesis and elicits anxiolytic-like activities. Trans Psychiatry 3: e253.
42. Rainer Q, Xia L, Guilloux JP, Gabriel C, Mocaer E, Hen R et al (2011). Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety. Int J Neuropsychopharmacol 1-15 (e-pub ahead of print).
43. Samuels BA, Leonardo ED, Gadient R, Williams A, Zhou J, David DJ et al (2011). Modeling treatment-resistant depression. Neuropharmacology 61: 408-413.
44. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S et al (2003). Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301: 805-809. (Pubitemid 36962615)
45. Schiavi GB, Brunet S, Rizzi CA, Ladinsky H (1994). Identification of serotonin 5-HT4 recognition sites in the porcine caudate nucleus by radioligand binding. Neuropharmacology 33: 543-549. (Pubitemid 24168726)
46. Schmidt EF, Warner-Schmidt JL, Otopalik BG, Pickett SB, Greengard P, Heintz N (2012). Identification of the cortical neurons that mediate antidepressant responses. Cell 149: 1152-1163.
47. Silvestre JS, Fernandez AG, Palacios JM (1996). Effects of 5-HT4 receptor antagonists on rat behaviour in the elevated plus-maze test. Eur J Pharmacol 309: 219-222. (Pubitemid 26273738)
48. Surget A, Tanti A, Leonardo ED, Laugeray A, Rainer Q, Touma C et al (2011). Antidepressants recruit new neurons to improve stress response regulation. Mol Psychiatry 16: 1177-1188.
49. Tamburella A, Micale V, Navarria A, Drago F (2009). Antidepressant properties of the 5-HT4 receptor partial agonist, SL65.0155: behavioral and neurochemical studies in rats. Prog Neuropsychopharmacol Biol Psychiatry 33: 1205-1210.
50. Tonini M, Pace F (2006). Drugs acting on serotonin receptors for the treatment of functional GI disorders. Dig Dis 24: 59-69.
51. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L et al (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163: 28-40. (Pubitemid 43050100)
52. Wang JW, David DJ, Monckton JE, Battaglia F, Hen R (2008). Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J Neurosci 28: 1374-1384. (Pubitemid 351231535)
53. Warner-Schmidt JL, Flajolet M, Maller A, Chen EY, Qi H, Svenningsson P et al (2009). Role of p11 in cellular and behavioral effects of 5-HT4 receptor stimulation. J Neurosci 29: 1937-1946.
54. Wong EH, Yocca F, Smith MA, Lee CM (2010). Challenges and opportunities for drug discovery in psychiatric disorders: the drug hunters' perspective. Int J Neuropsychopharmacol 13: 1269-1284.
55. Xia L, Delomenie C, David I, Rainer Q, Marouard M, Delacroix H et al (2012). Ventral hippocampal molecular pathways and impaired neurogenesis associated with 5-HT(1)A and 5-HT(1)B receptors disruption in mice. Neurosci Lett 521: 20-25.